Companies›Healthcare›Healthcare›Healthcare Services
NSE:VIMTALABS

VIMTA LABS LIMITED

Healthcare › Healthcare Services
₹510.00
at close · 28 Oct 2026
▼ 1.20 (-0.23%)

Latest filings

Next results: Fri, 30 Oct · Financial Results
  1. Vimta Labs sets Q2 FY27 investor call for October 30 · Board & Shareholder Meetings
  2. Board meeting set to approve September quarter and half-year results · Results
  3. RTA compliance certificate for Sep 2026 quarter · Compliance
All filings ↓
Ask Nexa about VIMTA LABS LIMITED

Snapshot

What the business is, and whether it's a good one at a fair price.

AI · written from filings

Provides contract research and laboratory testing services to pharmaceutical, food and environmental, and electronics companies. Operations run out of a ~200,000 sq ft Genome Valley lab campus that is ~60% occupied. The pharma contract research arm is delivering consistent year-on-year growth, while the clinical research arm is showing early signs of recovery after prior-year challenges. Biologics contract research and development services were recently launched, with a first customer order already secured, though meaningful P&L contribution is only expected from the third year onwards. Food and environmental testing is under pressure from Middle East trade disruption, with the business pivoting toward domestic clients. Electronics and electrical testing has stabilised after prior leadership issues and benefits from a 15.19% YoY increase in the defence budget. Employees are the largest cost at 28.1% of revenue, followed by materials at 19.8% and other operating expenses at 17.3%.

Operating scale
Genome Valley lab infrastructure
~200,000 sq ft, ~60% occupiedQ1 FY27
Q1 FY27 total income
₹1,129 million (+13.7% YoY)Q1 FY27
Q1 FY27 EBITDA margin
36.4%Q1 FY27
FY22–FY26 revenue CAGR
17%FY22–FY26
FY22–FY26 EBITDA CAGR
16.2%FY22–FY26
FY27 capex plan
~₹80 crore (₹10 cr Biologics + ₹70 cr routine)FY27
Who pays it
Pharmaceutical, biotechnology, food, electronics and defence companies requiring contract research and laboratory testing
Biggest cost
Employee costs at 28.1% of revenue
Kind of business
Asset-heavy contract research and testing services across pharma, food, electronics and environment
Where it sits
Net debt-free with FY26 EBITDA margin of 35.8%, described by management as among the best in the industry globally
Market Cap
₹2,278 Cr
P / E (TTM)
18.4×
EV / EBITDA
19.8×
Div Yield
0.19%
Growth
8.4%▲
Revenue 5y CAGR
PAT +10.1% · EBITDA +8.8%
Quality
16.4%▲
ROCE (5y median)
ROE 12.8% (5y median) · margin 28.5%
Leverage
0.06·
Debt / Equity · low
Net cash ₹2.65 Cr
Revenue FY19→FY24
1.5×▲
Margin +1.0 pts
₹213 Cr → ₹318 Cr
Cash conversion
1.61×▲
Operating cash ÷ profit · 4 yrs
₹245 Cr on ₹152 Cr
Moves on a normal day
1.46%·
Median daily move
Last 267 sessions · the yardstick for filing-day moves
Where it sits among 70 Healthcare Services peersBar = share of peers beaten · tick = industry median · latest reported figures
P/E (TTM)#21/63
P/B#39/57
ROCE#27/69
ROE#31/57
Debt / Equity#19/56
EBITDA margin#5/57
Revenue growth#44/57
Profit growth#8/55

Scorecard

Measured from the filed financials, judged against its Healthcare Services peers · as of FY24 — not investment advice

Strengths
Returns on capital 16.4% (5-year median)
#27 of 69 in Healthcare Services on the latest reported figures
Debt at 0.06× equity
lower than 67% of its 56 Healthcare Services peers
Over 4 years it reported ₹152 Cr of profit and ₹245 Cr of operating cash — 1.61×
Profit is converting into cash
Concerns
Nothing flagged in the filed numbers.

Charts

How has the market priced it — with filings on the timeline?

VIMTALABS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Peers

How does it stack up on valuation, returns and growth?

Loading peers…

Financials

Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.

Loading financials…

Ownership

Who owns it — and is the promoter stake clean?

Loading shareholding…

Sign up to see the full company file

Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.

Common questions

Answered from VIMTA LABS LIMITED's filed financials and exchange disclosures

What does VIMTA LABS LIMITED do?

VIMTA LABS LIMITED is a Healthcare Services company listed on NSE and BSE, trading under the symbol VIMTALABS.

Is VIMTA LABS LIMITED profitable?

Yes. Over the trailing twelve months VIMTA LABS LIMITED reported a net profit of ₹61 Cr on revenue of ₹336 Cr.

Does VIMTA LABS LIMITED pay a dividend?

Yes. The dividend yield is 0.19% at the current price. It paid out 11% of its profit as dividend in FY24.

Is VIMTA LABS LIMITED debt-free?

On a net basis, yes. It reported borrowings of ₹12 Cr on its 30 Sept 2024 balance sheet, but holds ₹2.65 Cr more cash than debt.

Is VIMTA LABS LIMITED expensive compared with its peers?

On trailing P/E, VIMTA LABS LIMITED ranks 21 of 63 in Healthcare Services — cheaper than 68% of them, against an industry median of 34.9×. This is a position, not a valuation judgement.

How much does the VIMTA LABS LIMITED share price move in a day?

On a typical session VIMTA LABS LIMITED moves 1.46% — that is the median absolute close-to-close move across its last 267 trading days. MarketPing measures each filing's price reaction against it.

When are VIMTA LABS LIMITED's next results?

Financial Results on Fri, 30 Oct. MarketPing alerts you on WhatsApp the moment the filing lands.

Where can I track VIMTA LABS LIMITED's announcements?

Every NSE and BSE filing by VIMTA LABS LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.

Figures are as last reported and may lag the latest filing. Not investment advice.